Skip to main content

Advertisement

Log in

A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab

  • Letter to the Editor
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14:561–584

    Article  PubMed  CAS  Google Scholar 

  2. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478–479

    Article  PubMed  Google Scholar 

  3. Leo M, Maggi F, Rotondo Dottore G, Casini G, Mazzetti P, Pistello M, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2017) Graves’ orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein–Barr virus infection: a serological and molecular study. J Endocrinol Invest 40:499–503

    Article  PubMed  CAS  Google Scholar 

  4. Li HX, Xiang N, Hu WK, Jiao XL (2016) Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest 39:1225–1233

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Marinò.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All diagnostic and therapeutic procedures performed in this study were in accordance with ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the individual participant included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sabini, E., Sframeli, A. & Marinò, M. A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab. J Endocrinol Invest 41, 877–878 (2018). https://doi.org/10.1007/s40618-018-0906-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-018-0906-0

Keywords

Navigation